Key Highlights

  • Net income rose 25.8% to USD 20.6 million in the third quarter of 2026, reported by UFP Technologies (NASDAQ:UFPT) on November 3, 2026, against USD 16.4 million a year earlier.
  • Net sales grew 11.6% to USD 172.4 million, including 11.1% organic growth, while MedTech sales increased 12.5% in the quarter.
  • GAAP Diluted Earnings per Share were USD 2.64 and adjusted diluted earnings per share were USD 2.88, compared with USD 2.11 and USD 2.39 in the third quarter of 2025.
  • Gross Margin widened to 29.4% from 27.7%, while selling, general and administrative expenses grew 21.4% to USD 23.2 million, or 13.4% of sales.

Third Quarter Profit Outpaces Sales

UFP Technologies (NASDAQ:UFPT), a contract development and Manufacturing organization for medical devices, sterile packaging and other engineered products, reported results for the quarter ended September 30, 2026 on November 3, 2026. Net sales rose 11.6% to USD 172.4 million, Operating Income rose 18.1% to USD 27.6 million, and Net Income rose 25.8% to USD 20.6 million. Adjusted operating income grew 14.5% to USD 30.1 million and adjusted EBITDA grew 15.3% to USD 35.4 million. For nine months, sales reached USD 500.6 million, up 10.3%, and net income reached USD 59.0 million, up 16.2%, with Organic Sales growth of 7.9%.

Margin Expansion and Lower Interest Behind the Gap

Profit outgrew sales for two visible reasons. Gross margin improved 1.7 points to 29.4%, and net interest expense fell to USD 1.5 million from USD 2.4 million, a reduction of about USD 0.9 million by simple arithmetic on the two reported figures. Long-term Debt including the current portion was USD 96.0 million on September 30, 2026, against about USD 135.5 million at December 31, 2025, also our arithmetic. Management cited scaling of new programs in the Dominican Republic and margin gains in legacy operations. Partly offsetting this, selling, general and administrative expenses grew 21.4%, faster than sales, and adjusted SG&A rose to 12.0% of sales from 10.7%. GAAP and adjusted earnings differ by about USD 0.24 per share this quarter, and adjusted figures are non-GAAP.

Behind-Plan Transfers, Customer Concentration and the Credit Facility

The company said scheduled program transfers to the Dominican Republic and margin improvement at AJR remain behind plan. Its risk disclosures also flag dependence on its two largest customers, the chance that Supply agreement volumes or rebates fall short, tariffs, a prior cyber incident and the risk that an effort to expand its credit Facility may not succeed on favorable terms. Management said it is working to enlarge the facility to fund acquisitions and has added capacity at DAS Medical for double-digit growth in 2027. Cash was USD 20.6 million and receivables and inventories both increased since December. A conference call was set for 8:30 a.m. ET on November 4, 2026.

Where Things Stand

Net income grew faster than sales mainly because gross margin expanded and interest costs fell, even as overhead rose faster than revenue. UFP Technologies (NASDAQ:UFPT) delivered 25.8% net income growth on 11.6% sales growth, with MedTech up 12.5%. The quality of the beat depends on whether margins hold while the Dominican Republic transfers catch up, whether acquisitions can be financed through a larger credit facility, and whether the two largest customers keep volumes steady. The call on November 4, 2026 should add detail on the 2027 growth plans management described as optimistic, and the company did not provide a formal outlook in the release extract reviewed.